Mana Capital Acquisition Corp. MAAQR
We take great care to ensure that the data presented and summarized in this overview for Mana Capital Acquisition Corp. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in MAAQR
Top Purchases
Top Sells
About MAAQR
Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.
Insider Transactions at MAAQR
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 06
2024
|
Robert Philibert Chief Medical Officer |
BUY
Open market or private purchase
|
Indirect |
34,075
+1.0%
|
$0
$0.29 P/Share
|
Sep 06
2024
|
Meeshanthini Dogan Chief Technology Officer |
BUY
Open market or private purchase
|
Direct |
137,930
+14.92%
|
$0
$0.29 P/Share
|
Mar 31
2024
|
Paul Frederick Burton Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,803
+50.0%
|
$8,803
$1.42 P/Share
|
Mar 31
2024
|
Stanley K. Lau Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,803
+8.07%
|
$8,803
$1.42 P/Share
|
Mar 31
2024
|
James Intrater Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,803
+10.95%
|
$8,803
$1.42 P/Share
|
Mar 31
2024
|
Oded Levy Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,803
+10.95%
|
$8,803
$1.42 P/Share
|
Jan 31
2024
|
Stanley K. Lau Director |
BUY
Exercise of conversion of derivative security
|
Direct |
917
+0.99%
|
$1,834
$2.18 P/Share
|
Dec 31
2023
|
Brandon Sim Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,020
+7.4%
|
$10,040
$2.49 P/Share
|
Dec 31
2023
|
James Intrater Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,020
+7.4%
|
$10,040
$2.49 P/Share
|
Dec 31
2023
|
Oded Levy Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,020
+7.4%
|
$10,040
$2.49 P/Share
|
Dec 31
2023
|
Stanley K. Lau Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,626
+3.55%
|
$13,252
$2.49 P/Share
|
Oct 31
2023
|
Stanley K. Lau Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,631
+7.32%
|
$0
$0.3 P/Share
|
Sep 30
2023
|
Stanley K. Lau Director |
BUY
Exercise of conversion of derivative security
|
Direct |
42,647
+22.44%
|
$0
$0.34 P/Share
|
Sep 30
2023
|
Oded Levy Director |
BUY
Exercise of conversion of derivative security
|
Direct |
36,765
+38.89%
|
$0
$0.34 P/Share
|
Sep 30
2023
|
James Intrater Director |
BUY
Exercise of conversion of derivative security
|
Direct |
36,765
+38.89%
|
$0
$0.34 P/Share
|
Sep 30
2023
|
Brandon Sim Director |
BUY
Exercise of conversion of derivative security
|
Direct |
36,765
+38.89%
|
$0
$0.34 P/Share
|
Aug 31
2023
|
Stanley K. Lau Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,637
+9.49%
|
$0
$0.55 P/Share
|
Aug 31
2023
|
Meeshanthini Dogan Chief Technology Officer |
BUY
Open market or private purchase
|
Indirect |
16,481
+11.38%
|
$0
$0.55 P/Share
|
Aug 31
2023
|
Timur Dogan Chief Technology Officer |
BUY
Open market or private purchase
|
Direct |
16,481
+11.38%
|
$0
$0.55 P/Share
|
Aug 28
2023
|
Robert Philibert Chief Medical Officer |
BUY
Open market or private purchase
|
Indirect |
18,000
+0.54%
|
$0
$0.59 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 57.8K shares |
---|---|
Open market or private purchase | 172K shares |